Design and synthesis of novel pegylated iron chelators with decreased metabolic rate.
暂无分享,去创建一个
V. Abbate | Xiaole Kong | R. Hider | S. Bansal | Xingyuan Zhang | Zidong Lu | Junpei Li | Yongmin Ma
[1] S. Srichairatanakool,et al. Characterisation of a novel oral iron chelator: 1‐(N‐Acetyl‐6‐Aminohexyl)‐3‐Hydroxy‐2‐Methylpyridin‐4‐one , 2015, The Journal of pharmacy and pharmacology.
[2] V. Abbate,et al. Deferitazole, a new orally active iron chelator. , 2015, Dalton transactions.
[3] R. Bergeron,et al. Desferrithiocin: A Search for Clinically Effective Iron Chelators , 2014, Journal of medicinal chemistry.
[4] E. Kool,et al. Genetically encoded multispectral labeling of proteins with polyfluorophores on a DNA backbone. , 2013, Journal of the American Chemical Society.
[5] R. Hider,et al. A novel fluorescence method for determination of pFe3+. , 2013, The Analyst.
[6] Xiaole Kong,et al. Chelating agents for the treatment of systemic iron overload. , 2012, Current medicinal chemistry.
[7] Vip Viprakasit,et al. A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. , 2012, Blood.
[8] F. Veronese,et al. The Impact of PEGylation on Biological Therapies , 2012, BioDrugs.
[9] Massimo Midiri,et al. Deferasirox, Deferiprone and Desferrioxamine Treatment in Thalassemia Major Patients: Cardiac Iron and Function Comparison Determined by Quantitative Magnetic Resonance Imaging Early Release Paper Deferasirox, Deferiprone and Desferrioxamine Treatment in Thalassemia Major Patients: Cardiac Iron and , 2022 .
[10] D. van der Helm,et al. Amido-3-hydroxypyridin-4-ones as iron(III) ligands. , 2010, Chemistry.
[11] H. Bobby Gaspar,et al. Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID) , 2009, Biologics : targets & therapy.
[12] U. Schaible,et al. Targeting the lysosome: fluorescent iron(III) chelators to selectively monitor endosomal/lysosomal labile iron pools. , 2008, Journal of medicinal chemistry.
[13] T. Pivetta,et al. Potentiometric, spectrophotometric and calorimetric study on iron(III) and copper(II) complexes with 1,2-dimethyl-3-hydroxy-4-pyridinone. , 2008, Journal of inorganic biochemistry.
[14] Gil Y. Melmed,et al. Certolizumab pegol , 2022, Nature Reviews Drug Discovery.
[15] T. Ganz,et al. Liver iron concentrations and urinary hepcidin in beta-thalassemia. , 2007, Haematologica.
[16] A. Cnaan,et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. , 2006, Blood.
[17] J. Porter,et al. Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia. , 2002, Best practice & research. Clinical haematology.
[18] J. Balfour,et al. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases. , 1999, Drugs.
[19] P. Gans,et al. Hyperquad simulation and speciation (HySS): a utility program for the investigation of equilibria involving soluble and partially soluble species , 1999 .
[20] P. Gans,et al. Determination of equilibrium constants from spectrophometric data obtained from solutions of known pH : The program pHab , 1999 .
[21] P. Gans,et al. Investigation of equilibria in solution. Determination of equilibrium constants with the HYPERQUAD suite of programs. , 1996, Talanta.
[22] P. Dobbin,et al. Synthesis, Physicochemical Properties, and Biological Evaluation of N- Substituted 2-Alkyl-3-hydroxy-4(1H)-pyridinones: Orally Active Iron Chelators with Clinical Potential. , 1994 .
[23] D. van der Helm,et al. Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential. , 1993, Journal of medicinal chemistry.
[24] P. Dobbin,et al. Urinary metabolic profiles in human and rat of 1,2-dimethyl- and 1,2-diethyl-substituted 3-hydroxypyridin-4-ones. , 1992, Drug metabolism and disposition: the biological fate of chemicals.